טוען...
Targeting p300/CBP in lethal prostate cancer
Resistance to androgen receptor (AR) blockade in castration resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of the AR (AR-SV). Inhibitors of transcriptional co-activators that regulate AR activity, including the paralogue histone-ace...
שמור ב:
| הוצא לאור ב: | Cancer Discov |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8102310/ https://ncbi.nlm.nih.gov/pubmed/33431496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-0751 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|